Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Gross Margin (2016 - 2025)

Cytosorbents' Gross Margin history spans 15 years, with the latest figure at 73.68% for Q4 2025.

  • Quarterly results put Gross Margin at 73.68% for Q4 2025, up 533.0% from a year ago — trailing twelve months through Dec 2025 was 71.48% (up 156.0% YoY), and the annual figure for FY2025 was 71.48%, up 156.0%.
  • Gross Margin for Q4 2025 was 73.68% at Cytosorbents, up from 70.28% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 77.46% in Q2 2021 to a low of 44.6% in Q3 2022.
  • The 5-year median for Gross Margin is 70.57% (2025), against an average of 67.35%.
  • The sharpest move saw Gross Margin plummeted -3017bps in 2022, then soared 1904bps in 2023.
  • Year by year, Gross Margin stood at 71.04% in 2021, then decreased by -14bps to 61.31% in 2022, then fell by 0bps to 61.27% in 2023, then rose by 12bps to 68.35% in 2024, then grew by 8bps to 73.68% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 73.68%, 70.28%, and 70.85% for Q4 2025, Q3 2025, and Q2 2025 respectively.